Skip to main content

Table 2 Treatment characteristics of included trials

From: Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials

First author Acronym Treatment dose Control dose Time from symptoms onset to first dose, days Patients in ICU at baseline, % Patients on IMV at baseline, % Patients who received steroids, % Primary outcome Longest follow-up
Gordon AC REMAP-CAP Tocilizumab: 8 mg/kg IV (max 800 mg); second dose 12–24 h at physician discretion; Sarilumab: 400 mg IV, one dose N/A N/A 100.0 29.0 90.7 Respiratory and cardiovascular organ support-free days up to day 21 Hospital stay
Hermine O CORIMUNO-TOCI 1 8 mg/kg IV (max 800 mg); second dose 400 mg on day 3 at discretion of attending physician N/A 10 0.0 0.0 47.7 Death or NIMV/IMV day 4 (WHO-CPS > 5); survival without MV on day 14 Hospital stay
Lescure FX N/A 400 mg IV or 200 mg IV. Second dose based on clinician’s discretion within 24–48 h N/A 5 35.6 11.6 42.1 Time to clinical improvement 60 days
RECOVERY Collaborative Group RECOVERY 800 mg if weight > 90 kg; 600 mg if weight > 65 and ≤ 90 kg; 400 mg if weight > 40 and ≤ 65 kg; and 8 mg/kg if weight ≤ 40 kg. A second dose could be given, according to the clinician opinion, if patient’s condition did not improve N/A 9 (tocilizumab) vs 10 (standard care) N/A 13.7 82.2 28-day mortality 28 days
Rosas IO COVACTA 8 mg/kg IV (max 800 mg); second dose 8–24 h after if no improvement/worsening N/A 11 (tocilizumab) vs 10 (placebo) 56.4 37.7 42.2 Clinical status on 7-category ordinal scale at day 28 28 days
Rutgers A PreToVid 8 mg/kg IV (max 800 mg); second dose 8 h after if hypoxia not resolved N/A 9 (tocilizumab) vs 9 (standard care) N/A N/A 88.4 30-day mortality 30 days
Salama C EMPACTA 8 mg/kg IV (max 800 mg); second dose 8–24 h after if no improvement/worsening N/A 8 15.4 0.0 82.8 Death or IMV/ECMO by day 28 60 days
Salvarani C RCT-TCZ-COVID-19 8 mg/kg IV (max 800 mg), 2 doses 12 h apart N/A 8 0.0 0.0 10.6 Clinical worsening within 14 days Hospital stay
Sivapalasingam S N/A 200 mg IV, 400 mg IV, or 800 mg IV N/A N/A N/A N/A 29.0 CRP levels (Phase 2); Clinical improvement in patients receiving MV at baseline (Phase 3) 29 days
Soin AS COVINTOC 6 mg/kg IV (max 480 mg); second dose 12 h–7d after if no improvement/worsening N/A N/A 65.9 5.0 91.1 Disease progression (from moderate to severe or from severe to death) within 14 days Hospital stay
Stone JH BACC Bay Tocilizumab Trial 8 mg/kg IV (max 800 mg) N/A 9 4.1 0.0 11.6 Death or IMV by day 28 28 days
Talaschian M N/A 8 mg/kg IV (max 800 mg) N/A N/A 0.0 0.0 33.3 28-day mortality 28 days
Veiga VC TOCIBRAS 8 mg/kg IV (max 800 mg) N/A 10 N/A 16.3 86.0 Clinical status at day 15 (seven-level ordinal scale) 29 days
Wang D N/A 400 mg IV; second dose 24 h if still fever N/A 23 N/A 0.0 N/A Cure rate of enrolled patients Hospital stay
Zhao H N/A 4–8 mg/kg IV; second dose 24 h if still fever 1600 mg × 2 p.p. day 1; 600 mg × 2 p.o. day 2–7 N/A N/A 0.0 N/A Cumulative lung lesion remission rate (lung CT examination indicated absorption of lung inflammation) Hospital stay
  1. CT: computed tomography; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IMV: invasive mechanical ventilation; IV: intravenous; N/A: not available; NIMV: non-invasive mechanical ventilation; WHO-CPS: World Health Organization Clinical Performance Scale